Meng Wenjun, Luo Yihang, Zhao Lu, Zhang Yaoyu, Liu Jiyan, Li Shadan, Du Yang, Li Hongshuai
Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Department of Urology, The General Hospital of Western Theater Command, Chengdu, China.
Front Oncol. 2024 Dec 20;14:1507608. doi: 10.3389/fonc.2024.1507608. eCollection 2024.
Although the number of studies on sorafenib for hepatocellular carcinoma (HCC) is increasing during the past two decades, no detailed scientometric examination of its knowledge framework has been undertaken. Therefore, we performed a bibliometric analysis on this topic.
VOSviewer and CiteSpace were utilized to analyze the articles regarding sorafenib for HCC from 2005 to 2024, which were retrieved from the Web of Science Core Collection (WoSCC) database.
There were 7,667 articles related to sorafenib in HCC were retrieved from the WoSCC database, and they covered 99 countries/regions, 5,640 institutions, and 30,450 authors. The most published literature of countries and institutions were China and Sun Yat-sen University, respectively. Cancers is the journal with the most papers published in this field, and the journal with the most co-citations is N Engl J Med. Among authors, Masatoshi Kudo has published the most research papers, and the most co-citations go to JM Llovet. The keywords "survival", "apoptosis", "efficacy", "transarterial chemoembolization", "lenvatinib", etc. represent the current hotspots in this field.
We identified current hotspots and trends by bibliometric analysis in sorafenib-HCC field, which might provide valuable guidance for future researches. Further explorations are supposed to conduct the continued study of HCC apoptosis, large-scaled clinical trials with international cooperations, and comprehensive treatments including multiple systemic or locoregional approaches in patients with HCC.
尽管在过去二十年中，关于索拉非尼治疗肝细胞癌（HCC）的研究数量不断增加，但尚未对其知识框架进行详细的科学计量学审查。因此，我们对该主题进行了文献计量分析。
利用VOSviewer和CiteSpace分析2005年至2024年期间从Web of Science核心合集（WoSCC）数据库中检索到的关于索拉非尼治疗HCC的文章。
从WoSCC数据库中检索到7667篇与HCC中索拉非尼相关的文章，它们覆盖了99个国家/地区、5640个机构和30450名作者。发表文献最多的国家和机构分别是中国和中山大学。Cancers是该领域发表论文最多的期刊，被引频次最高的期刊是《新英格兰医学杂志》。在作者中，工藤雅史发表的研究论文最多，被引频次最高的是洛弗特。关键词“生存”“凋亡”“疗效”“经动脉化疗栓塞”“乐伐替尼”等代表了该领域当前的热点。
我们通过文献计量分析确定了索拉非尼-HCC领域当前的热点和趋势，这可能为未来的研究提供有价值的指导。进一步的探索应该继续研究HCC凋亡、开展国际合作的大规模临床试验，以及对HCC患者采用包括多种全身或局部治疗方法的综合治疗。
